Cardiovascular risk markers and mechanisms in targeting the COX pathway for colorectal cancer prevention.

Oates JA
Cancer Prev Res (Phila). 2011 4 (8): 1145-8

PMID: 21816843 · DOI:10.1158/1940-6207.CAPR-11-0333

COX-2 inhibition reduces the incidence of colorectal neoplasia. The increased risk of thrombotic cardiovascular events produced by selective or nonselective COX-2 inhibitors, however, has confounded the consideration of employing them in cancer prevention. Developing a strategy for preventing colorectal cancer by inhibiting COX-2 depends on research advances in several key areas, including predictive biomarkers to identify people at the lowest risk for cardiovascular events, the molecular mechanisms whereby interdicting the COX-2 pathway produces thrombotic events, and the pharmacology of the widely divergent agents that act on COX-2 and its downstream pathway.

MeSH Terms (10)

Adenoma Anticarcinogenic Agents C-Reactive Protein Celecoxib Colorectal Neoplasms Female Humans Male Pyrazoles Sulfonamides

Connections (2)

This publication is referenced by other Labnodes entities: